APG Asset Management US Inc. Sells 666 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

APG Asset Management US Inc. decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,334 shares of the pharmaceutical company's stock after selling 666 shares during the period. APG Asset Management US Inc.'s holdings in Vertex Pharmaceuticals were worth $2,148,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. ABC Arbitrage SA acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $1,510,000. Czech National Bank raised its holdings in shares of Vertex Pharmaceuticals by 6.2% in the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company's stock valued at $22,486,000 after purchasing an additional 3,260 shares during the last quarter. Highview Capital Management LLC DE boosted its stake in shares of Vertex Pharmaceuticals by 1.8% during the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock worth $2,324,000 after buying an additional 102 shares during the last quarter. Davidson Investment Advisors grew its stake in Vertex Pharmaceuticals by 26.0% in the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock valued at $24,630,000 after buying an additional 12,631 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in Vertex Pharmaceuticals by 75.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock worth $994,000 after buying an additional 1,062 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

VRTX has been the subject of several recent analyst reports. Bank of America upped their price objective on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and increased their price objective for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. StockNews.com upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, March 11th. Stifel Nicolaus increased their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research note on Monday, December 16th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $512.41.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Ourania Tatsis sold 530 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares of the company's stock, valued at approximately $27,825,928.26. This represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock worth $2,121,012 in the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Trading Up 1.7 %

NASDAQ VRTX traded up $8.46 during trading hours on Monday, hitting $492.68. 401,270 shares of the company's stock were exchanged, compared to its average volume of 1,322,509. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The business's 50 day moving average is $484.84 and its 200-day moving average is $464.28. The firm has a market capitalization of $126.52 billion, a P/E ratio of -223.95, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.